Skip to main content
main-content

29-09-2021 | ESMO 2021 | Conference coverage | Video

Dual EphrinB2 pathway, PD-1 inhibition shows promise in metastatic UC setting

Sarmad Sadeghi talks about their phase 2 trial pointing to the potential of combining the novel EphrinB2 pathway inhibitor sEphB4-HSA with pembrolizumab in previously treated patients with metastatic urothelial carcinoma (3:51).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Read transcript

ESMO Congress 2021

Access our ongoing coverage including the latest news and expert video interviews.

Image Credits